Inventor · disambiguated record
Kevin Lewis Otipoby
Also filed as: OTIPOBY KEVIN · OTIPOBY KEVIN LEWIS
14 granted patents·19 pending applications·80 citations·filing 2014–2025
90Inventor score
Files withPANDION OPERATIONS INC18PANDION THERAPEUTICS INC7SEISMIC THERAPEUTIC INC6BIOGEN MA INC1PANDION OPERATION INC1
Top patents by PatentIndex Score
33 records- 0197US10174091B1IL-2 muteinsPANDION THERAPEUTICS INC·Filed 2018·Granted Jan 8, 2019·31 cites·25 claims
- 0297US10174092B1IL-2 muteinsPANDION THERAPEUTICS INC·Filed 2018·Granted Jan 8, 2019·28 cites·25 claims
- 0394US11091527B2IL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2019·Granted Aug 17, 2021·5 cites·2 claims
- 0493US11091526B2IL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2019·Granted Aug 17, 2021·4 cites·2 claims
- 0593US10946068B2IL-2 muteins and uses thereofPANDION THERAPEUTICS INC·Filed 2018·Granted Mar 16, 2021·9 cites·27 claims
- 0689US2024239858A1Il-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2024·Application pending·0 cites
- 0789US2024247039A1Il-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2024·Application pending·0 cites
- 0886US12030945B2Variant IgG Fc polypeptides and uses thereofSEISMIC THERAPEUTIC INC·Filed 2023·Granted Jul 9, 2024·1 cites·30 claims
- 0980US11965008B2IL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2021·Granted Apr 23, 2024·0 cites·19 claims
- 1079US11945852B2IL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2021·Granted Apr 2, 2024·0 cites·22 claims
- 1177US11981715B2Tissue targeted immunotolerance with a CD39 effectorPANDION OPERATIONS INC·Filed 2021·Granted May 14, 2024·1 cites·7 claims
- 1276US12129499B2Protease variants and uses thereofSEISMIC THERAPEUTIC INC·Filed 2024·Granted Oct 29, 2024·0 cites·25 claims
- 1374US2019169255A1Il-2 muteins and uses thereofPANDION THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1470US2025027068A1Protease variants and uses thereofSEISMIC THERAPEUTIC INC·Filed 2024·Application pending·0 cites
- 1570US2025002582A1Targeted immunotolerance with a pd-1 agonistPANDION OPERATIONS INC·Filed 2024·Application pending·0 cites
- 1670US2019169254A1Il-2 muteins and uses thereofPANDION THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1769USRE50550EIL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2022·Granted Aug 26, 2025·0 cites·27 claims
- 1869US2025074984A1VARIANT IgG FC POLYPEPTIDES AND USES THEREOFSEISMIC THERAPEUTIC INC·Filed 2024·Application pending·0 cites
- 1966US10280169B2Biaryl bruton's tyrosine kinase inhibitorsBIOGEN MA INC·Filed 2014·Granted May 7, 2019·1 cites·16 claims
- 2062US11779632B2IL-2 muteins and uses thereofPANDION OPERATION INC·Filed 2021·Granted Oct 10, 2023·0 cites·20 claims
- 2160US2024368283A1Molecules for modulating the immune system and uses thereofSEISMIC THERAPEUTIC INC·Filed 2024·Application pending·0 cites
- 2258US2024228619A9Pancreas targeted therapeutics and uses thereofPANDION OPERATIONS INC·Filed 2022·Application pending·0 cites
- 2357US2025019431A1Kidney targeted immunotolerancePANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 2454US2021206856A1Targeted immunotolerance with a pd-1 agonistPANDION THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2552US2024301064A1Pd-1 antibodies, polypeptides and uses thereofPANDION OPERATIONS INC·Filed 2022·Application pending·0 cites
- 2651US2024010722A1Madcam targeted therapeutics and uses thereofPANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 2751US2024262905A1Skin targeted immunotolerancePANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 2851US2024052034A1Multi-paratopic anti-pd-1 antibodies and uses thereofPANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 2949US2022041713A1Targeted immunotolerancePANDION OPERATIONS INC·Filed 2019·Application pending·0 cites
- 3047US2023235004A1Tissue targeted immunotolerance with pd-1 agonists or il-2 muteinsPANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 3146US11739146B2MAdCAM targeted immunotolerancePANDION OPERATIONS INC·Filed 2020·Granted Aug 29, 2023·0 cites·9 claims
- 3245US2021277085A1Targeted immunotolerancePANDION THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3343US2025340857A1IgE PROTEASES AND USES THEREOFSEISMIC THERAPEUTIC INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kevin Lewis Otipoby files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →